Press Releases 2018

Below you can access Liminal BioSciences press releases for 2018. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.

  • Prof. Simon Best appointed interim CEO of Prometic Life Sciences

    Prof. Simon Best appointed interim CEO of Prometic Life Sciences

    Prometic announced today that it has named Prof. Simon Best as Interim Chief Executive Officer, effective immediately.

    Read Article
  • Press Releases 2019

    Read More
  • Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

    Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

    The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU regulatory agencies.

    Read Article
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Prometic provides corporate update

    Prometic provides corporate update

    This includes a significant reduction in the Corporation’s cash use in 2019, driven by significant growth in its bioseparation revenues & a reduction of anticipated R&D expenditures by up to $30m.

    Read Article
  • Prometic reports third quarter 2018 financial results and highlights

    Prometic reports third quarter 2018 financial results and highlights

    Implementation of cost control measures to significantly reduce operational burn and extend cash runway

    Read Article
  • Prometic closes its extension of debt maturities to 2024

    Prometic closes its extension of debt maturities to 2024

    Maturity Dates of the Line of Credit and Long-Term (OID) Loans extended to September 2024

    Read Article
  • Prometic to report its third quarter 2018 financial results and hold conference call / webcast

    Prometic to report its third quarter 2018 financial results and hold conference call / webcast

    Prometic announced today that it will report its financial results for the third quarter ended September 30, 2018 on Wednesday November 14, 2018 after market close.

    Read Article
  • Prometic announces extension of debt maturities to 2024

    Prometic announces extension of debt maturities to 2024

    As a result of the extension, the maturity dates of the Debt will be amended to September 2024, requiring no repayment of the sums borrowed until then.

    Read Article
  • Prometic announces second annual plasminogen deficiency awareness week

    Prometic announces second annual plasminogen deficiency awareness week

    This initiative, sponsored by Prometic, aims to raise awareness and improve understanding of this rare disease and its effects. Plasminogen Deficiency Awareness Week is a free 4-day online event

    Read Article
  • Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA

    Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA

    Implementation plan for additional analytical assays and in-process controls confirmed and PLI finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing

    Read Article
  • Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome

    Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome

    Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndrome (AS).

    Read Article
  • Prometic reports second quarter 2018 financial results and highlights

    Prometic reports second quarter 2018 financial results and highlights

    Prometic has advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).

    Read Article
  • Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology

    Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology

    n the ongoing Phase 2 clinical trial in patients with Alström syndrome, PBI-4050 was shown to significantly reduce liver and cardiac fibrosis.

    Read Article
  • Prometic to report its second quarter 2018 financial results and hold conference call / webcast

    Prometic to report its second quarter 2018 financial results and hold conference call / webcast

    Prometic announced today that it will report its financial results for the second quarter ended June 30, 2018 on Tuesday August 14, 2018 after market close.

    Read Article
  • Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050

    Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050

    In addition to the Rare Pediatric Disease Designation, PBI-4050 was previously granted Orphan Drug Designation by the FDA and the EMA for the treatments of AS and idiopathic pulmonary fibrosis (IPF).

    Read Article
  • Prometic conference call to present progress report on AGM corporate action plan

    Prometic conference call to present progress report on AGM corporate action plan

    Prometic it will hold a conference call on Wednesday June 27, 2018 to report on its progress in implementing the updated corporate plan presented during its AGM on Wednesday May 9th 2018.

    Read Article
  • Prometic presents new data on NASH drug candidate PBI-4547

    Prometic presents new data on NASH drug candidate PBI-4547

    New data suggest PBI-4547 offers potential as novel therapy for liver fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), diabetes and obesity.

    Read Article
  • Prometic presents new clinical data on PBI-4050 for the treatment of Idiopathic Pulmonary Fibrosis

    Prometic presents new clinical data on PBI-4050 for the treatment of Idiopathic Pulmonary Fibrosis

    Treatment with PBI-4050 for 12 weeks positively affected biomarkers known to have antifibrotic activity

    Read Article
  • Prometic reports its 2018 first quarter highlights and financial results

    Prometic reports its 2018 first quarter highlights and financial results

    Clinical programs streamlined to manage costs for balance of 2018 and continued positive clinical activity demonstrated by PBI-4050 to catalyze partnership discussions

    Read Article
  • Prometic reports on its 2018 annual and special meeting of shareholders highlights

    Prometic reports on its 2018 annual and special meeting of shareholders highlights

    Prometic continued in 2017 its transition that has transformed the company into a biopharmaceutical company with two drug discovery platforms focusing on rare and orphan diseases.

    Read Article
  • Prometic reports positive clinical data from its intravenous immunoglobulin (IVIG) pivotal phase 3 trial

    Prometic reports positive clinical data from its intravenous immunoglobulin (IVIG) pivotal phase 3 trial

    Prometic’s IVIG demonstrated comparable safety and efficacy data to existing commercial IVIG products without any significant drug related safety issues.

    Read Article
  • loading
    Loading More...